In human studies, mean plasma myostatin levels were significantly higher in patients with T2DM [56,57] and subjects with metabolic syndrome and impaired glucose–insulin homeostasis with lower muscle mass [112]. This evidence concerns the gene MSTN and type 2 diabetes mellitus.